1 week Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)Seeking Alpha Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade). AbbVie (ABBV) X
1 week AbbVie’s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology PortfolioYahoo Finance X
1 week Bristol Rockets 11% As Investors Question AbbVie’s $8.7 Billion ‘Mistake’Investor's Business Daily X
3 weeks AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPSMarketBeat X
3 weeks AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, RinvoqInvesting.com X
3 weeks AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter BeatInvestor's Business Daily X
4 weeks Mediolanum International Funds Ltd Reduces Stock Position in AbbVie Inc. (NYSE:ABBV)MarketBeat X
4 weeks Foundations Investment Advisors LLC Has $12.81 Million Position in AbbVie Inc. (NYSE:ABBV)MarketBeat X